• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

FDA approves new combination parasite preventive

February 28, 2020
dvm360 Staff

The sarolaner-moxidectin-pyrantel chewable is 100% effective both in preventing heartworm and in killing adult fleas 8 hours after treatment.

Zoetis has announced the FDA approval of Simparica Trio, the first isoxazoline combination product to provide comprehensive protection against the most common internal and external parasites, according to a company release.

Through the combination of sarolaner, moxidectin and pyrantel, Simparica Trio protects dogs against heartworm disease, fleas, ticks (Amblyomma americanum, Amblyomma maculatum, Dermacentor variabilis, Ixodes scapularis, and Rhipicephalus sanguineus),roundworms (immature and adult Toxocara canis and adult Toxascaris leonina) and hookworms (Ancylostoma caninum and Uncinaria stenocephala).The product is approved for use in dogs 8 weeks and older weighing at least 2.8 lb, and is expected to be available by late April.

“Comprehensive parasite protection is a critical component of every annual wellness exam, and veterinarians should strongly recommend year-round, broad-spectrum protection for all patients,” said Chris Adolph, DVM, MS, DACVM (Parasitology), senior veterinary specialist at Zoetis, in the release. “Simparica Trio makes it easier for dog owners to follow their veterinarians’ recommendations for parasite protection because it covers the most common parasites in just one convenient chewable.”

Advertisement

Simparica Trio should be used with caution in dogs with a history of seizures. Sarolaner, one of the active ingredients in Simparica Trio, has been associated with neurologic adverse reactions including tremors, ataxia and seizures in dogs with or without a history of neurologic disorders.

The safe use of Simparica Trio has not been evaluated in breeding, pregnant or lactating bitches. The most commonly reported adverse effects in clinical trials were vomiting and diarrhea.

Treatment with Simparica Trio can begin at any time of the year and should be administered year‑round at monthly intervals. For more information about this product, visit simparicatriodvm.com.

Related Content:

MedicalClinicalTechniciansAssociatesProducts
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
New Automatic 2-in-1 Pet Feeder and Water Dispenser launched
Alternate therapies for pain management
Alternate therapies for pain management

Advertisement

Latest News

Drug for acute onset of canine pancreatitis is launched on the US market

New Automatic 2-in-1 Pet Feeder and Water Dispenser launched

PetHub launches AI tools for pet owners

Prairie dog pups emerge from underground at Maryland Zoo

View More Latest News
Advertisement